Ralph T Doyle Selected Research

eicosapentaenoic acid ethyl ester

1/2022	Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI.
1/2022	Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction.
12/2021	Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG.
11/2021	Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL.
10/2021	Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT.
1/2021	Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses.
10/2020	Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies.
1/2020	REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States.
11/2019	Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT.
8/2019	Icosapent ethyl reduces atherogenic markers in high-risk statin-treated patients with stage 3 chronic kidney disease and high triglycerides.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ralph T Doyle Research Topics

Disease

9	Hypertriglyceridemia 01/2022 - 07/2007
9	Cardiovascular Diseases (Cardiovascular Disease) 11/2021 - 05/2016
2	Myocardial Infarction 01/2022 - 11/2021
2	Stroke (Strokes) 01/2022 - 11/2021
2	Hemorrhage 11/2021 - 01/2019
2	Atrial Fibrillation 11/2021 - 01/2019
2	Diabetes Mellitus 01/2020 - 01/2018
2	Atherosclerosis 01/2020 - 11/2019
2	Pain (Aches) 05/2002 - 01/2002
1	Infarction (Infarctions) 01/2022
1	Unstable Angina 11/2021
1	Coronary Artery Disease (Coronary Atherosclerosis) 10/2020
1	Chronic Renal Insufficiency 08/2019
1	Type 2 Diabetes Mellitus (MODY) 01/2018
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 08/2015
1	Gastroesophageal Reflux (GERD) 10/2010
1	Dyslipidemias (Dyslipidemia) 05/2010
1	Overweight 09/2009
1	Pancreatitis 09/2009
1	Body Weight (Weight, Body) 09/2009
1	Dyspepsia (Indigestion) 07/2007
1	Diarrhea 07/2007
1	Nasopharyngitis 07/2007
1	Respiratory Tract Infections (Respiratory Tract Infection) 07/2007
1	Breakthrough Pain 05/2002
1	Low Back Pain (Lumbago) 01/2002

Drug/Important Bio-Agent (IBA)

16	eicosapentaenoic acid ethyl esterIBA 01/2022 - 05/2015
14	Triglycerides (Triacylglycerol)IBA 01/2021 - 09/2009
12	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2022 - 07/2007
7	LDL CholesterolIBA 12/2021 - 05/2010
4	LipidsIBA 01/2018 - 07/2007
3	EstersIBA 06/2019 - 07/2007
2	oxidized low density lipoproteinIBA 08/2019 - 08/2015
2	Eicosapentaenoic AcidIBA 06/2019 - 01/2016
2	Lipoproteins (Lipoprotein)IBA 05/2016 - 07/2007
2	Simvastatin (Zocor)FDA LinkGeneric 05/2010 - 07/2007
2	Analgesics (Analgesic Drugs)IBA 05/2002 - 01/2002
1	LDL Lipoproteins (beta Lipoproteins)IBA 01/2021
1	Mineral Oil (Liquid Paraffin)FDA LinkGeneric 10/2020
1	remnant-like particle cholesterolIBA 10/2016
1	Apolipoprotein C-IIIIBA 05/2016
1	C-Reactive ProteinIBA 08/2015
1	Nizatidine (Axid)FDA LinkGeneric 10/2010
1	Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA 09/2009
1	Fenofibrate (CiL)FDA LinkGeneric 09/2009
1	Omacor FDA Link 07/2007
1	Pharmaceutical PreparationsIBA 07/2007
1	Opioid Analgesics (Opioids)IBA 05/2002
1	Hydromorphone (Dilaudid)FDA LinkGeneric 05/2002
1	Ibuprofen (Motrin)FDA LinkGeneric 01/2002
1	Oxycodone (Oxycontin)FDA LinkGeneric 01/2002
1	TabletsIBA 01/2002
1	Acetaminophen (Paracetamol)FDA LinkGeneric 01/2002
1	Hydrocodone (Dihydrocodeinone)FDA LinkGeneric 01/2002

Therapy/Procedure

7	Therapeutics 10/2020 - 05/2002